The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

BZ Group
  • 3.0 (4)
  • Life Sciences
  • Updated Daily

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

  1. 13h ago

    Week in Review | AstraZeneca’s Setback, Novartis Under Pressure & Scholar Rock’s Approval

    AstraZeneca's broader-use trial of Etcamah (camizestrant)missed its primary goal in advanced breast cancer, while the existing approval stands. Scholar Rock's ISEMBYLD (apitegromab) adds a muscle-directed option inspinal muscular atrophy, while Roivant's mosliciguat links vascular improvement with better walking distance in pulmonary hypertension associated with interstitial lung disease. Novartis faces pipeline and acquisition scrutiny asBiohaven pauses new BHV-7000 enrollment and Karyopharm confronts near-term financing pressure. Encoded's ETX101 results frame its Dravet syndromefinancing, and BioNTech's lung-cancer presentations lead the week ahead. Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.

  2. 2d ago

    Exelixis Faces FDA Delay & Karyopharm Faces October Deadline

    FDA extended its review of Exelixis's zanzalintinib-Tecentriq combination for metastatic colorectal cancer to March 3, 2027, after classifying updated data as a major amendment. Karyopharm missed a $15.8 million loan payment and secured a creditor standstill through October 15 tied partly to its selinexor-ruxolitinib myelofibrosis filing. Roche's Enspryng gained Priority Review in MOGAD; COSCIENS bought oral-film manufacturer Nualtis, and Frazier raised more than $1.1 billion for its Public Fund. Plus, Telix's Pixclara FDA decision remained unverified at our reporting cutoff. Alex Mercer and Maya Patel host the Daily Roundup for September 11. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  3. 3d ago

    Biohaven Faces FDA Enrollment Hold & AbbVie Reports Menstrual Migraine Results

    Biohaven's FDA partial hold pauses new epilepsy-trialenrollment; the company still expects RISE-3 results this year. AbbVie reports LUNA menstrual-migraine results for oral Qulipta (atogepant), while Shionogi misses a stroke endpoint and Disc Medicine reports fewer blood-removalprocedures in early polycythemia vera data. Novartis faces shareholder pressure, Solstice raises $225 million, and MannKind partners with Rose Pharma on inhaled weight management. NICE questions the value of Gilead's lenacapavir for HIV prevention, and new consensus guidance addresses type 1 diabetes screening. Alex Mercer and Maya Patel host the Daily Roundup forSeptember 10. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  4. 4d ago

    Bayer's Hyrnuo Enters First-Line Rivalry & FDA Gets Permanent Center Chiefs

    Bayer's Hyrnuo (sevabertinib) gains first-line accelerated approval in HER2-mutant lung cancer, joining an established rival. Permanent FDA center leaders follow repeated turnover, while Structure's experimental obesity pill aleniglipron adds 72-week follow-up without a concurrent placebo. Kura, EMD Serono and Encoded back new development efforts; Tyra reports early bladder cancer responses, Evommune changes its eczema program, and Beeline advances lupus studies. BioMarin's Voxzogo (vosoritide) filing targets hypochondroplasia, and Nanoscope reports application acceptance for severe retinitis pigmentosa. Alex Mercer and Maya Patel host the Daily Roundup for September 9. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.

  5. 5d ago

    Novartis's HARBOR Miss Tests Confidence in the Growth Plan & Rasonque's Access Hurdles

    Novartis's del-desiran missed HARBOR's primary endpoint in myotonic dystrophy, adding pressure to a growth plan already facing setbacks. Roivant and Pulmovant's mosliciguat data advance Monday's PHocus preview, while AstraZeneca, Pharvaris, Amgen, Inhibrx and Bristol Myers add clinical updates across lung disease, hereditary angioedema and cancer. BrainChild Bio's financing, the proposed Sernova-Seraxis merger and Intellia's lonvo-z Priority Review round out the slate. Two resolved Rasonque access cases show why Revolution Medicines' pancreatic cancer launch requires more than approval: patients still need to navigate authorization, support and dispensing. Alex Mercer and Maya Patel host the Daily Roundup for September 8. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.

  6. 5d ago

    Novo Ends Two Ziltivekimab Heart-Failure Trials & SynAct Plans Another Arthritis Trial

    Novo is ending the HERMES and ATHENA ziltivekimab trials after a monitoring committee judged them unlikely to succeed, leaving ARTEMIS as its remaining Phase 3 cardiovascular path. We examine ADARx's IPO filing, the Aptar-Aceso ACT-101 collaboration in cystic fibrosis, and STEP Young semaglutide results in children ages six to under twelve. SynAct's resomelagon reanalysis asks what another rheumatoid arthritis trial must prove after two primary-endpoint misses. This late Labor Day edition reflects information available through Monday and previews Roivant and Pulmovant's PHocus mosliciguat data in pulmonary hypertension associated with interstitial lung disease. Alex Mercer and Maya Patel host the Daily Roundup for September 7. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  7. Sep 7

    Week in Review | Bristol's CAR-T Pause Was Three Months Old Before the Public Heard

    Bristol Myers Squibb told regulators in early June. The rest of us found out this week, after an analyst note. Three months sat between those two facts, and that gap is the story of the week. Also this week, a cardiovascular outcomes trial in more than eight thousand patients missed its endpoint and put a whole drug class in question. A mid-stage lupus readout took fifty five percent off a company in a day. And the FDA approved a cancer drug over its own advisers, while memos surfaced on a second approval it had granted over its own reviewers. What do you do with a week like that? Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  8. Sep 5

    Novartis's Pelacarsen Misses—What's Next for Rivals? & FDA Approves Etcamah Before Progression

    Novartis's pelacarsen missed its cardiovascular endpoint despite lowering Lp(a)—what should Amgen and Lilly rethink? FDA accelerated approval brings AstraZeneca's Etcamah (camizestrant) to ESR1-mutated, HR-positive, HER2-negative advanced breast cancer before progression, with confirmatory benefit still required. Following Monday's CAR-T coverage, new reporting traces Bristol Myers Squibb's notifications to early June, months before public confirmation. Also: Revolution Medicines' Rasonque (daraxonrasib) data in previously treated RAS-mutant lung cancer, and Superluminal's $60 million financing for rare genetic and hypothalamic obesity. Alex Mercer and Maya Patel host the Daily Roundup for September 4. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

See All (151)

Ratings & Reviews

3
out of 5
4 Ratings

About

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

Information